Abstract: Objective To evaluate the efficacy of Nasonex and montelukast sodium in the treatment of adenoidal hypertrophy. Methods We conducted a systematic literature search of Pub Med, Wangfang, and the Chinese National Knowledge VIP database 2010-2020 for Nasonex and montelukast sodium treatment in children with adenoidal hypertrophy. Standard articles were screened according to inclusion and exclusion criteria. The methodological quality of trials was evaluated with the Cochrane Handbook criteria, and the Review Manager 5.3 Revman5.1 software used for Meta-analyses. Finally, eleven articles, describing 865 patients, were selected, and included in the meta-analysis. Results The meta-analysis showed that the total effective rate of Nasonex combined with montelukast sodium(“the combination drug”)was significantly higher than that of Nasonex alone(“the single drug”)in the treatment of adenoidal hypertrophy in children(OR=4.29, 95%CI［2.72, 6.77］, P<0.000 01). The combination drug also caused a significant decrease in the A/N ratio(adeniod/nasopharynx ratio))(MD =-0.06, 95%CI［-0.10, -0.03］, P<0.000 1), and lowered clinical symptoms(MD=-1.40, 95%CI［-1.57, -1.23］). The combination drug significantly improved the quality of sleep in comparison to the single drug(MD=-1.40, 95%CI［-1.60, -1.20］, P<0.000 01). The combination group also demonstrated lower effects on the impact on daily functioning than the single drug group(MD=-1.07, 95%CI［-1.22, -0.93］, P<0.000 01). Conclusion Based on the current research and analysis, Nasonex combined with montelukast sodium has a significant clinical effect in the treatment of adenoidal hypertrophy in children. It is also a better choice to relieve various clinical symptoms and reduce the volume of adenoids than Nasonex alone. There was no literature that reported obvious adverse reactions.

Key words: Adenoidal hypertrophy in children, Nasonex, Montelukast(singular), Effective rate, Randomized controlled trial